

Thank you for viewing this presentation.

We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.

© 2007 by the author



European Respiratory
Society

Pathology of preneoplasia and common lung cancers

Elisabeth Brambilla

**INSERM U823 Department of Pathology
CHU Grenoble France**

Lung Cancer Classification revised in 1999 (WHO)

- 17 years elapsed since the 1981 WHO classification
- Progress in understanding genetic and molecular basis of carcinogenesis
- Foundation for tumor diagnosis and patient therapy
- Cornerstone of comparative studies: clinical, epidemiologic and biological
- Complemented with clinical and genetic features of entities : **Pathology and genetics (WHO 2004)**

Histological classification of lung tumors (WHO 1999 - 2004)

Squamous Cell Carcinoma

Small Cell Carcinoma

Adenocarcinoma

Large Cell Carcinoma

Adeno Squamous Carcinoma

Sarcomatoid carcinoma

Carcinoid tumors


Salivary gland tumors

Preinvasive lesions


Preinvasive lesions

- Squamous dysplasia
 - mild
 - moderate
 - severe
- Carcinoma in situ
- Atypical adenomatous hyperplasia (AAH)
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia


Normal bronchial epithelium




Bronchial epithelium: hyperplasia




Squamous metaplasia




Mild dysplasia




Moderate dysplasia




Severe dysplasia



Carcinoma in situ



Invasive carcinoma: T1



Pre- and neoplastic bronchial lesions

Hyperplasia



Metaplasia



Dysplasia



In situ carcinoma



Invasive carcinoma

Molecular Identity


. **Cell cycle regulation**


. **Apoptosis / Senescence**

. **Angiogenesis / Migration**

Atypical Alveolar Hyperplasia (AAH)

- **A preinvasive lesion for Bronchiolo Alveolar Carcinoma (BAC)**
- **Focal lesion (1-10 mm) most often less than 3mm**
- **Slightly atypical epithelial cells covering alveoli and respiratory bronchioles**
- **Differential diagnosis with BAC**
 - **size \geq 5mm**
 - **no gaps between cells**
 - **more severe atypia**






Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia

- **A proliferation of neuroendocrine cells confined to the bronchiolar epithelium**
- **Scattered single cells, small nodules or linear proliferations**
- **Often associated with tumourlets**


Neuroendocrine hyperplasia




Neuroendocrine hyperplasia



Tumourlet



Tumourlet : less than 5mm > 5mm : carcinoid



Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia

- **Idiopathic:** not a simple reaction to lung inflammation of fibrosis
- **A preneoplastic lesions:** some patients develop one or more carcinoid tumors
- A subset of patients have obstructive airway disease

Squamous cell carcinoma

A malignant epithelial tumour showing keratinization and/or intercellular bridges

Variants:


Papillary

Clear cell


Small cell

Basaloid


Squamous cell carcinoma




Squamous cell carcinoma



Squamous cell carcinoma: papillary variant



Squamous cell carcinoma: basaloid variant



Small Cell Carcinoma

WHO 1999-2004

WHO 1981

Small Cell Carcinoma


Small Cell Carcinoma

Variant


Oat cell


- **Combined Small Cell Carcinoma**


Intermediate Combined













NCAM




NCAM-PSA


SCLC: NCAM




SCLC: Chromogranin



SCLC: TTF1



SCLC combined



WHO 1999 - 2004

Adenocarcinoma

- . **Adenocarcinoma mixed subtype**
- . Acinar adenocarcinoma
- . Papillary adenocarcinoma
- . **Bronchioloalveolar carcinoma**
 - Non-mucinous
 - Mucinous
 - Mixed mucinous - non mucinous
- . Solid adenocarcinoma with mucin
- . Variants:

WHO 1981


Adenocarcinoma

- Acinar
- Papillary
- Bronchioloalveolar carcinoma
- Solid adenocarcinoma with mucus formation


Adenocarcinoma

- 85% display mixed histology
 - **Adenocarcinoma mixed type**: more than one subtype
- **Bronchioloalveolar carcinoma**
restrictive definition: a non invasive tumor


Adenocarcinoma: acinar




Adenocarcinoma: papillary



Bronchioloalveolar carcinoma (BAC)



BAC : Clara Cell Type



Bronchioloalveolar carcinoma (BAC)

- **Pure “lepidic” growth pattern along respected alveolar walls**
 - **No invasion (stromal, vascular, pleural)**
 - **No central scar, no desmoplastic stromal reaction**
 - **No papillary structures in alveolar lumens**
- Most previously reported BAC are now adenocarcinoma mixed sub type**
- The diagnosis of BAC cannot be achieved on small biopsies**

Bronchioloalveolar carcinoma (non invasive)

Significant association with

- pathological stage I

$p < 0,001$

- absence of lymph node metastasis

$p < 0,001$

- 5 years patient survival among stage I cases


$p < 0,005$

Noguchi M. (type AB-BAC < 2cm) Cancer 1995


Yokose et al Lung Cancer 2000

Suzuki et al Ann Thorac Surg 2002

BAC : mucinous type




Mucinous BAC : satellite lesion





2cm Adenocarcinoma






Central scar : Acinous adenocarcinoma





Periphery : BAC component



Bronchioloalveolar carcinoma: clinical significance

- **Less than 2 cm BAC can be curable by economic surgical resection:**

100% - 5 year survival

Noguchi et al Cancer 1995

- **Size of central scar in ADC with peripheral BAC less than 3cm**

– **< 5mm 100% 5 year survival**


– **5-15mm 71% 5 year survival**

– **≥ 15mm 40% 5 year survival**

independent prognostic factor p = 0.01

Suzuki et al. Ann Thorac Surg 2000

Terasaki et al Am. J. Surg. Pathol. 2003



WHO 1999

1.3.4. Large cell carcinoma

Variants:

1.3.4.1. Large cell neuroendocrine carcinoma

Combined large cell neuroendocrine carcinoma


1.3.4.2. Basaloid carcinoma

1.3.4.3. Lymphoepithelioma-like carcinoma


1.3.4.4. Clear cell carcinoma

1.3.4.5. Large cell carcinoma with rhabdoid phenotype


Large cell carcinoma: NOS



Large Cell Neuroendocrine Carcinoma (LCNEC)




NCAM



Large Cell Neuroendocrine Carcinoma (LCNEC)

- A variant of large cell carcinoma
- A high grade NE tumor
- Characteristic features
 - Neuroendocrine morphology (rosettes ...)
 - Non small cell cytology (≠ SCLC)
 - High mitotic rate ≥ 11 per 2mm^2
(≠ Atypical carcinoid)
- 15 - 20% of LCNEC are **Combined LCNEC**

LCNEC combined



LCNEC: clinical features

- **Heavy smokers. Mean age 62 years**
- **Poor prognosis: 27% - 5 y. survival**
9% - 10 y. survival
- **Not significantly different from SCLC**
- **Surgical resection recommended**
- **Chemotherapy sensitivity?**

SCLC chemotherapy type ?

Rossi et al JCO 2005

The spectrum of neuroendocrine (NE) proliferation and neoplasms

I - NE cell hyperplasia and tumorlets

A. NE cell hyperplasia

B. Tumorlets

II - Tumors with NE morphology

A. Typical carcinoid

B. Atypical carcinoid


C. Large cell neuroendocrine carcinoma


D. Small cell carcinoma

III - Non small cell carcinomas with NE differentiation

Lung neuroendocrine tumors

- **Carcinoids:** **Typical carcinoid**
Atypical carcinoid
 - ➔ **Sharp histopathological definition**
 - ➔ **Significant prognostic differences**






Carcinoids: Typical versus Atypical

	Mitoses	Necrosis	5y. survival	10y. survival
Typical carcinoid	< 2/ 2mm ²	0	87%	87%
Atypical carcinoid	2-10/ 2mm ²	+/-	56%	35%

W.D. Travis Am. J. Surg. Pathol. 1998

PULMONARY NE TUMORS

KAPLAN MEIER SURVIVAL ESTIMATION




AFIP/IASLC NE STUDY 8-97 (N=331; 78 TC, 81 AC, 78 LCNEC, 88 SCLC)


Large cell carcinoma

- **Large cell carcinoma :**
 - no clinical significance
- **Two variants with clinical significance**
 - **Large cell neuroendocrine carcinoma (5%)**
 - **Basaloid carcinoma (5%)**


Basaloid carcinoma

- Proliferation of "reserve" stem cells
- No neuroendocrine markers
- High proliferative index
- Poor prognosis





Survival of stage I BC vs NSCLC



WHO 1999 - 2004

Sarcomatoid carcinomas

Pleomorphic carcinoma

Spindle cell carcinoma


Giant cell carcinoma

Carcinosarcoma


Pulmonary blastoma

Sarcomatoid carcinoma

- Express the features of epithelial to mesenchymal transition
- Pleiomorphic carcinoma: 10% of giant or spindle cells
- Large peripheral tumors often invading chest and with endobronchial growth
- Differential diagnosis: sarcoma



Ker.



Pleomorphic Carcinoma (Sarcomatoid carcinoma)

- **Poor prognosis**
 - median survival: 19 months
 - 47% - 5 year survival at stage I

Rossi et al Am J. Surg Pathol 2003

→ **Disease related survival significantly shorter than NSCLC stage I**

Immuno histochemistry

Electron microscopy



Differential diagnosis

- **Large cell Neuroendocrine Carcinoma / Basaloid**
- **Carcinoma**
- **Adenocarcinoma / Mesothelioma (calretinin, CK5-6, ACE...)**
- **Adenocarcinoma / Primitive / Metastatic (TTF1)**
- **Pleiomorphic carcinoma / Sarcoma (Ck)**
- **Sarcoma (desmin, E.M.)**
- **Melanoma (HMB45, S100)**



World Health Organization Classification of Tumours



Pathology & Genetics

Tumours of the Lung, Pleura, Thymus and Heart

Edited by William D. Travis, Elizabeth Brambilla,
Hans K. Muller-Hermelink & Curtis C. Harris

WHO Classification Tumours of the Lung, Pleura, Thymus and Heart

